Stephanie Hummel1, Hugo Van Aken, Alexander Zarbock. 1. aDepartment of Anesthesiology, Intensive Care and Pain Medicine, University of Muenster bMax-Plank Institute Muenster, Muenster, Germany.
Abstract
PURPOSE OF REVIEW: The CXC chemokine receptor type 4 (CXCR4), which is a G-protein coupled receptor, and its ligand CXCL12 play an important role in neutrophil homeostasis and inflammation. This review focuses on involvement of the CXCL12/CXCR4 axis in inflammation and different inflammatory diseases and depicts that blocking CXCR4 is an attractive therapeutic strategy. RECENT FINDINGS: Binding of CXCL12 to CXCR4 retains immature neutrophils in the bone marrow and also participates in leukocyte recruitment into inflamed tissue. The CXCL12/CXCR4 axis is also involved in several inflammatory processes and diseases including the WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome, HIV, autoimmune disorders, ischemic injury, and pulmonary fibrosis. SUMMARY: Based on these findings, blocking CXCR4 seems to be a therapeutic strategy in inflammatory diseases. Several promising CXCR4 antagonists are in different stages of development and clinical trials. Currently, only plerixafor (AMD3100) has been approved for short-term application.
PURPOSE OF REVIEW: The CXC chemokine receptor type 4 (CXCR4), which is a G-protein coupled receptor, and its ligand CXCL12 play an important role in neutrophil homeostasis and inflammation. This review focuses on involvement of the CXCL12/CXCR4 axis in inflammation and different inflammatory diseases and depicts that blocking CXCR4 is an attractive therapeutic strategy. RECENT FINDINGS: Binding of CXCL12 to CXCR4 retains immature neutrophils in the bone marrow and also participates in leukocyte recruitment into inflamed tissue. The CXCL12/CXCR4 axis is also involved in several inflammatory processes and diseases including the WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome, HIV, autoimmune disorders, ischemic injury, and pulmonary fibrosis. SUMMARY: Based on these findings, blocking CXCR4 seems to be a therapeutic strategy in inflammatory diseases. Several promising CXCR4 antagonists are in different stages of development and clinical trials. Currently, only plerixafor (AMD3100) has been approved for short-term application.
Authors: Nicholas A Manieri; Madison R Mack; Molly D Himmelrich; Daniel L Worthley; Elaine M Hanson; Lars Eckmann; Timothy C Wang; Thaddeus S Stappenbeck Journal: J Clin Invest Date: 2015-08-17 Impact factor: 14.808
Authors: Katherine Griffiths; Olan Dolezal; Benjamin Cao; Susan K Nilsson; Heng B See; Kevin D G Pfleger; Michael Roche; Paul R Gorry; Andrew Pow; Katerina Viduka; Kevin Lim; Bernadine G C Lu; Denison H C Chang; Thomas Murray-Rust; Marc Kvansakul; Matthew A Perugini; Con Dogovski; Marcel Doerflinger; Yuan Zhang; Kathy Parisi; Joanne L Casey; Stewart D Nuttall; Michael Foley Journal: J Biol Chem Date: 2016-04-01 Impact factor: 5.157
Authors: Terrence E Riehl; David Alvarado; Xueping Ee; Aaron Zuckerman; Lynn Foster; Vaishali Kapoor; Dinesh Thotala; Matthew A Ciorba; William F Stenson Journal: Gut Date: 2018-06-22 Impact factor: 23.059
Authors: Benjamin P Burke; Cecilia S Miranda; Rhiannon E Lee; Isaline Renard; Shubhanchi Nigam; Gonçalo S Clemente; Thomas D'Huys; Torsten Ruest; Juozas Domarkas; James A Thompson; Timothy J Hubin; Dominique Schols; Christopher J Cawthorne; Stephen J Archibald Journal: J Nucl Med Date: 2019-06-14 Impact factor: 11.082